home / stock / jmac / jmac quote
Last: | $10.81 |
---|---|
Change Percent: | -2.64% |
Open: | $11.824 |
Close: | $10.81 |
High: | $12.72 |
Low: | $10.08 |
Volume: | 117,874 |
Last Trade Date Time: | 03/29/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$10.81 | $11.824 | $10.81 | $12.72 | $10.08 | 117,874 | 03-29-2023 |
$11.52 | $11.48 | $11.52 | $12.97 | $10.75 | 70,945 | 03-28-2023 |
$11.19 | $11.35 | $11.19 | $12.8999 | $10.71 | 62,401 | 03-27-2023 |
$11.8 | $13 | $11.8 | $13.73 | $10.92 | 114,182 | 03-24-2023 |
$11.85 | $12.95 | $11.85 | $19.22 | $10.0001 | 308,249 | 03-23-2023 |
$13.88 | $10.95 | $13.88 | $18 | $10.21 | 1,013,394 | 03-22-2023 |
$8.85 | $11.975 | $8.85 | $11.975 | $7.5 | 177,686 | 03-21-2023 |
$11.69 | $11.4 | $11.69 | $12.02 | $10.75 | 15,266 | 03-20-2023 |
$11.13 | $10.25 | $11.13 | $15.78 | $9.955 | 318,554 | 03-17-2023 |
$10.1 | $9.83 | $10.1 | $11.11 | $9.8 | 31,766 | 03-16-2023 |
$10.2237 | $10.13 | $10.2237 | $10.39 | $9.58 | 23,025 | 03-15-2023 |
$10.5001 | $10.5 | $10.5001 | $10.53 | $10.46 | 47,129 | 03-14-2023 |
$10.53 | $10.5 | $10.53 | $10.53 | $10.5 | 50,409 | 03-13-2023 |
$10.5 | $10.5 | $10.5 | $10.5 | $10.5 | 567 | 03-10-2023 |
$10.5 | $10.5 | $10.5 | $10.5 | $10.5 | 228 | 03-09-2023 |
$10.51 | $10.51 | $10.51 | $10.52 | $10.51 | 62,418 | 03-08-2023 |
$10.505 | $10.505 | $10.505 | $10.51 | $10.5 | 7,542 | 03-07-2023 |
$10.51 | $10.51 | $10.51 | $10.51 | $10.51 | 16,717 | 03-06-2023 |
$10.51 | $10.49 | $10.51 | $10.51 | $10.49 | 2,700 | 03-03-2023 |
$10.5 | $10.49 | $10.5 | $10.5 | $10.49 | 22,235 | 03-02-2023 |
News, Short Squeeze, Breakout and More Instantly...
Maxpro Capital Acquisition Corp. Company Name:
JMAC Stock Symbol:
NASDAQ Market:
FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today...
FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) ha...
TAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”), deposited an additional payment in the aggregate ...